Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
BRAF V600E/K PTEN loss
|
Advanced Solid Tumor
|
predicted - sensitive |
|
PX-866 + Vemurafenib
|
Phase I |
Actionable |
In a Phase I trial, the combination therapy of PX-866 and Zelboraf (vemurafenib) demonstrated safety and resulted in an objective response in 28% (5/18) of advanced solid tumor patients harboring BRAF V600E or K, and of those five patients, 80% (4/5) also demonstrated loss of PTEN (PMID: 29051322).
|
29051322
|